EPIRUS Biopharmaceuticals, Inc. (EPRS) financial statements (2020 and earlier)

Company profile

Business Address 699 BOYLSTON ST
BOSTON, MA 02116
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2015
12/31/2014
12/31/2013
12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments3221185
Cash and cash equivalents3221185
Receivables  33
Prepaid expense11 
Prepaid expense and other current assets1
Other current assets10 
Other undisclosed current assets20030
Total current assets:35232138
Noncurrent Assets
Property, plant and equipment2124
Intangible assets, net (including goodwill)3322718
Goodwill2616  
Intangible assets, net (excluding goodwill)66718
Restricted cash and investments2222
Other noncurrent assets00 
Other undisclosed noncurrent assets 4  
Total noncurrent assets:37281123
TOTAL ASSETS:72513261
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities78610
Accounts payable2223
Accrued liabilities4435
Employee-related liabilities 112
Interest and dividends payable 0  
Settlement liabilities1 
Debt15 713
Deferred revenue and credits1025
Deferred tax liabilities00  
Other liabilities01  
Other undisclosed current liabilities10(1)(0)(8)
Total current liabilities:3371520
Noncurrent Liabilities
Long-term debt and lease obligation 729
Long-term debt, excluding current maturities 729
Liabilities, other than long-term debt2201
Deferred revenue and credits1101
Deferred tax liabilities, net01  
Other liabilities01 0
Other undisclosed noncurrent liabilities1   
Total noncurrent liabilities:39210
Total liabilities:36171729
Stockholders' equity
Stockholders' equity attributable to parent36321431
Common stock0000
Additional paid in capital175119394372
Accumulated other comprehensive income (loss)(0)  0
Accumulated deficit(139)(87)(380)(341)
Total stockholders' equity:36321431
Other undisclosed liabilities and equity 211
TOTAL LIABILITIES AND EQUITY:72513261

Income statement (P&L) ($ in millions)

12/31/2015
12/31/2014
12/31/2013
12/31/2012
Revenues
(Revenue, Net)
101513
Cost of revenue
(Cost of Goods and Services Sold)
(0)   
Gross profit:101513
Operating expenses(53)(39)(52)(55)
Operating loss:(52)(39)(37)(43)
Nonoperating income (expense)(0)(3)00
Investment income, nonoperating  00
Other nonoperating income (expense)(0)000
Interest and debt expense (0)(1)(2)
Other undisclosed income from continuing operations before equity method investments, income taxes 0  
Loss from continuing operations before income taxes:(53)(42)(39)(45)
Income tax benefit10 0
Net loss available to common stockholders, diluted:(52)(42)(39)(44)

Comprehensive Income ($ in millions)

12/31/2015
12/31/2014
12/31/2013
12/31/2012
Net loss:(52)(42)(39)(44)
Comprehensive loss:(52)(42)(39)(44)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0) (0)0
Comprehensive loss, net of tax, attributable to parent:(52)(42)(39)(44)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: